Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
ISSN
01406736
Date Issued
2017
Author(s)
DOI
10.1016/S0140-6736(17)32290-0
Subjects